Bringing a new therapy to market is one of the most complex undertakings in the pharmaceutical industry. Brand teams invest years planning clinical development, regulatory submissions, market access strategies, and launch execution, all with the goal of reducing uncertainty and maximizing the opportunity for commercial success.

Yet despite this planning, many launches still fail to meet expectations. Deloitte’s analysis of U.S. drug launches found that 34% of drugs launched between 2012 and 2021 missed their launch forecasts, with factors including limited market access and an inadequate understanding of market and customer needs contributing to underperformance.

In many cases, it’s not because the science isn’t strong or the launch plan wasn’t executed well. It’s because some of the most significant commercialization risks were never identified in the first place.

These risks don’t typically appear on project timelines, but they emerge when patients struggle to start treatment, healthcare professionals (HCPs) encounter unexpected barriers, or support programs fail to reflect how care is delivered in the real world. By the time these issues become visible, they have often already affected adoption, patient engagement and long-term brand performance.

As pharmaceutical companies increasingly focus on delivering connected, patient-centred experiences, commercialization planning is evolving beyond launch execution alone. Deloitte’s Global Life Sciences Outlook highlights that future success will depend on organizations’ ability to integrate data, digital capabilities and patient-centric strategies across the product lifecycle – not simply bring new therapies to market.

The challenge for today’s brand teams is no longer just preparing for launch. It’s understanding the hidden risks that could influence commercial success long before they become visible.

The risks your launch plan probably doesn’t measure

Traditional launch planning measures readiness through milestones.

  • Regulatory approval
  • Manufacturing
  • Market access
  • Sales force readiness
  • Promotional materials

These are important.

But they don’t tell you whether patients will remain engaged six months after launch.

Or whether healthcare professionals have confidence using your therapy.

Or whether your support services actually reduce friction across the patient journey.

Some of the highest-impact commercialization risks include:

  • Patients overwhelmed by treatment complexity
  • HCP uncertainty around monitoring or administration
  • Fragmented digital experiences
  • Low engagement with support services
  • Poor medication persistence
  • Lack of actionable real-world insights

These risks rarely appear on dashboards.

Yet they have a direct impact on adoption.

Why assumptions create commercial risk

No launch strategy is built without assumptions. The risk lies in assuming those assumptions are correct.

During commercialization planning, brand teams make countless decisions about how patients will access treatment, how HCPs will adopt a new therapy, and what support patients will need throughout their treatment journey. But without validating these assumptions through patient insights, HCP feedback and real-world evidence, they can quickly become hidden barriers to success.

For example, a support program may be designed around the information patients should need, rather than the questions they actually ask. Educational resources may not align with how HCPs incorporate a new therapy into clinical practice. Even well-designed digital tools can struggle to drive engagement if they don’t fit naturally into patients’ lives or existing clinical workflows.

Patient support programs play an important role in helping patients navigate the clinical and logistical challenges associated with specialty medicines. Research has also highlighted the opportunity for these programs to generate real-world data that can help address evidence gaps and inform healthcare decision-making.

For brand teams, these insights can provide a clearer picture of what happens beyond treatment initiation, helping identify barriers and opportunities to strengthen support as patients move through their treatment journey.

The strongest commercialization strategies don’t eliminate uncertainty – they reduce it. By validating assumptions before launch, pharmaceutical companies can create more connected patient and HCP experiences, improve engagement and strengthen long-term commercial performance.

Technology doesn’t eliminate risk – it reveals it

AI and digital health are transforming pharmaceutical commercialization, creating new opportunities to personalize patient support, improve engagement and generate real-world insights.

However, technology alone doesn’t reduce commercialization risk.

Without a clear understanding of the patient journey, HCP workflows and the behavioural factors that influence treatment decisions, even the most advanced digital solutions can fall short. Technology can identify patterns, but it can’t determine which barriers matter most or how best to address them.

The strongest commercialization strategies combine behavioural science, patient journey mapping, AI-enabled insights and human expertise. Together, these capabilities help brands identify risks earlier, deliver more meaningful support and continuously optimize programs as patient needs evolve.

Commercialization is a continuous process – not a launch event

One of the biggest misconceptions in pharmaceutical launches is that commercialization ends after approval.

In reality, that’s when learning begins.

Questions brands should continue asking include:

  • Where are patients dropping off?
  • Which HCPs need additional education?
  • Which engagement channels drive the greatest value?
  • Which support interventions improve persistence?
  • What real-world evidence should influence future strategy?

Organizations that treat commercialization as an ongoing learning cycle adapt faster and build stronger long-term performance.

The brands that outperform aren’t better at launching.

They’re better at learning.

The highest-performing pharmaceutical companies don’t assume they’ve eliminated commercialization risk before approval.

They build systems that continuously identify it.

That means:

  • Listening to patients.
  • Understanding healthcare professional behaviours.
  • Measuring engagement—not just enrollment.
  • Combining technology with human insight.
  • Refining programs based on real-world evidence.

Commercialization becomes an ongoing process of optimization rather than a fixed launch plan.

That’s where sustainable competitive advantage is created.

The right partner helps you discover what you don’t yet know

Technology providers implement platforms.

Strategic partners challenge assumptions.

At RxPx, we help pharmaceutical companies uncover commercialization risks before they affect patients, HCP or launch performance.

Our approach combines strategic consulting, behavioural science, AI-enabled technology and human expertise to identify hidden barriers, strengthen patient engagement and continuously improve commercialization strategies throughout the product lifecycle.

Because successful commercialization isn’t about reacting faster.

It’s about seeing further.

Take the Brand Risk Assessment

Every launch has visible risks.

The most valuable insights come from uncovering the invisible ones.

Our Brand Risk Assessment helps pharmaceutical companies identify hidden commercialization risks, evaluate patient engagement opportunities and build strategies that improve launch readiness and long-term success.

Take the Brand Risk Assessment today and discover what your launch plan may be missing.